Natera’s USD 450 Million Foresight Deal Shows the Race for Residual Disease Dominance
Minimal Residual Disease Testing Heads Toward USD 7.2 Billion as Liquid Biopsy and Sequencing Reshape Cancer Monitoring Minimal Residual Disease Market is expanding as oncologists look for earlier and more precise ways to detect cancer cells that remain after treatment. According to Polaris Market Research, the industry was valued at USD 2.38 billion in 2025 and is estimated at USD 2.69 billion...
0 Commentarios 0 Acciones 26 Views 0 Vista previa
AC Mingle https://acmingle.com